BioCryst Pharmaceuticals Aktie
WKN: 896047 / ISIN: US09058V1035
|
07.07.2025 13:44:46
|
BioCryst Pharma Appoints Babar Ghias As CFO
(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX), a biotechnology company, on Monday announced the appointment of Babar Ghias as Chief Financial Officer and Head of corporate development.
Ghias has been working as CFO since 2022 at AvenCell Therapeutics.
Chief Executive Officer Jon Stonehouse said the addition of these skills and expertise to the leadership team is exactly what we need at this time.
In the pre-market trading, BioCryst Pharmaceuticals is 0.45% lesser at $8.90 on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioCryst Pharmaceuticalsmehr Nachrichten
|
02.11.25 |
Ausblick: BioCryst Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
03.08.25 |
Ausblick: BioCryst Pharmaceuticals veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) |
Analysen zu BioCryst Pharmaceuticalsmehr Analysen
Aktien in diesem Artikel
| BioCryst Pharmaceuticals | 6,14 | -1,06% |
|